R CIN 450 mg
|Pack Size||Qty||Price Per Pill or Unit||Price||Offer|
|30 Capsules||US$ 0.39||US$ 11.55||
|60 Capsules||US$ 0.38||US$ 23.08||
|90 Capsules||US$ 0.38||US$ 34.62||
|US Brand Name||Rifadin|
R cin for oral administration contains 450 mg of Rifampicin per capsule. It is indicated for treating all forms of tuberculosis, including chronic, advanced, and drug-resistant cases. Rifampicin should be used with at least one other medicine to treat tuberculosis by killing the bacteria population completely. It is also used to prevent bacterial meningitis or H influenza in individuals exposed to a primary case.
R cin capsule should be taken on an empty stomach at least an hour before or two hours after a meal to ensure rapid and complete absorption. Patients with liver problems should be closely observed for signs of toxicity. R cin must not be given to patients with severe liver disease. Use in premature and newborn infants, treatment with Rifampicin should be considered only in emergencies if a doctor prescribes it.
Rcin is contraindicated in the following conditions:
— In patients hypersensitive to this drug and with a history of previous sensitivity to any of the rifamycins or any of the ingredients present in the formulation
— Premature and newborn infants in whom the liver is not functioning well. Patients should be given Rifampicin only in cases of necessity and then with caution and under strict supervision.
— Rifampicin passes into the breast milk and should not be used during lactation.
— R cin is contraindicated when given currently with the combination of ritonavir/saquinavir.
— Rifampicin has been shown to cause liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease.
— The medicine should not be used in pregnant women with childbearing potential. If the treatment is judged to be essential, such treatment should be implemented only after carefully weight
Concurrent use of hepatitis C antiviral drugs (such as sofosbuvir, simeprevir, daclatasvir, and telaprevir) and R cin 450 should be avoided. Concomitant antacid administration may decrease the absorption of Rifampicin. Daily doses of R cin should be given at least an hour before the ingestion of antacids.
Concomitant use of paracetamol with R cin 450 may increase the known risk of hepatotoxicity concerning each medicine.
Rifampicin may accelerate the metabolism and may reduce the activity of medicines such as anticonvulsants, antiestrogens, antifungals, beta blockers, oral anticoagulants, antiarrhythmics, calcium channel blockers, clofibrate, corticosteroids, antiretroviral drugs, antipsychotics, antiretroviral drugs etc.
Adjusting the doses if you are already using any of the above drugs may be necessary. Patients should be warned that treatment may produce a reddish colouration of urine, saliva, and tears.
R cin is well tolerated by most patients at currently recommended doses, although gastrointestinal tolerance can be unacceptably severe. Other side effects, such as skin rashes, influenza-like syndrome, fever, and thrombocytopenia, are more likely to occur with intermittent administration. Temporary dyspnoea and anaemia have also been reported in patients taking the drug three times weekly. Inform your doctor immediately if you develop any side effect that persists for longer or becomes bothersome.